Order by Title | Order by Session Handouts will be shown as submitted.

Session: MO - A-BRM - Imaging for Target Definition Symposium Title: How Are We Going to Define Targets in 20 Years? Byline: S Bentzen1 *, (1) University of Wisconsin, Madison, WI Contact Email: bentzen@humonc.wisc.edu     Session: TU - A-BRM - Quantitative Imaging Symposium Title: How Can We Improve Quantification? Byline: E Jackson1 *, (1) M.D. Anderson Cancer Center, Houston, TX Contact Email: ejackson@mdanderson.org     Session: MO - A-BRM - Imaging for Target Definition Symposium Title: How Do We Define the Treatment Target? Byline: A.J. van der Kogel , Radboud University Nijmegen Medical Center, Department Radiation Oncology, Nijmegen, The Netherlands Contact Email: A.vanderKogel@rther.umcn.nl     Session: MO - A-BRM - Imaging for Target Definition Symposium Title: How Do We Image the Treatment Target? Byline: V Gregoire1 *, (1) , , Contact Email: vincent.gregoire@uclouvain.be     Session: TU - A-BRM - Quantitative Imaging Symposium Title: How Important Is Quantification? Byline: M Schnall1 *, (1)  University of Pennsylvania, Philadelphia, PA Contact Email: marcy.roche@uphs.upenn.edu     Session: MO - C-BRM - Imaging for Treatment Assessment Symposium Title: Imaging for Treatment Assessment: Are We Forgetting Normal Tissue? Byline: L Marks1 *, S Das2 , M Lawrence3 , J Bailey4 , (1) University of North Carolina, Chapel Hill, North Carolina, (2) Duke University, Durham, North Carolina, (3) University of North Carolina, Chapel Hill, North Carolina, (4) University of North Carolina, Chapel Hill, North Carolina Contact Email: marks@med.unc.edu     Session: MO - -BRM - Welcome and Introduction Title: Introduction Byline: R Jeraj1 *, (1) University of Wisconsin, Madison, Madison, WI Contact Email: rjeraj@wisc.edu     Session: TU - C-BRM - Industry, Regulatory Issues Symposium Title: NCI Initiatives: Imaging As a Biomarker for Therapy Response Byline: L Clarke, National Cancer Institute, Rockville, MD Contact Email: lclarke@mail.nih.gov     Session: TU - C-BRM - Industry, Regulatory Issues Symposium Title: Tumor Imaging for Treatment and Response Evaluation-Regulatory Issues Byline: Gerald H. Sokol MD, CDER/DOPP, FDA, Silver Spring, Md. Contact Email: Gerald.Sokol@fda.hhs.gov     Session: MO - C-BRM - Imaging for Treatment Assessment Symposium Title: What Can Anatomical Treatment Assessment Tell Us? Byline: D Jaffray1 *, (1) Princess Margaret Hospital, Toronto, ON, CA Contact Email: david.jaffray@rmp.uhn.on.ca     Session: TU - A-BRM - Quantitative Imaging Symposium Title: What Can We Learn From Each Other? Byline: D Sullivan1 *, (1) Duke Cancer Center, Durham, NC Contact Email: daniel.sullivan@duke.edu